Zealand’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Shares of Zealand Pharma A/S are up more than 2 percent in premarket trading after the company announced that its Phase III treatment for severe hypoglycemia hit the mark.